myeloid leukemia

Summary

Summary: Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors in the bone marrow and other sites.

Top Publications

  1. ncbi Molecular classification of cancer: class discovery and class prediction by gene expression monitoring
    T R Golub
    Whitehead Institute Massachusetts Institute of Technology Center for Genome Research, Cambridge, MA 02139, USA
    Science 286:531-7. 1999
  2. pmc MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1
    Ramiro Garzon
    Department of Medicine, Ohio State University, Columbus, 43210, USA
    Blood 113:6411-8. 2009
  3. ncbi Internal tandem duplication of the flt3 gene found in acute myeloid leukemia
    M Nakao
    Department of Internal Medicine III, Kyoto Prefectural University of Medicine, Japan
    Leukemia 10:1911-8. 1996
  4. ncbi Prognostically useful gene-expression profiles in acute myeloid leukemia
    Peter J M Valk
    Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
    N Engl J Med 350:1617-28. 2004
  5. ncbi Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)
    John C Byrd
    Division of Hematology and Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus 43210 1240, USA
    Blood 100:4325-36. 2002
  6. ncbi The transcriptional network that controls growth arrest and differentiation in a human myeloid leukemia cell line
    Harukazu Suzuki
    RIKEN Omics Science Center, RIKEN Yokohama Institute, Kanagawa, Japan
    Nat Genet 41:553-62. 2009
  7. ncbi FLT3 mutations in acute myeloid leukemia cell lines
    H Quentmeier
    DSMZ German Collection of Microorganisms and Cell Cultures, Department of Human and Animal Cell Cultures, Braunschweig, Germany
    Leukemia 17:120-4. 2003
  8. ncbi The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United King
    P D Kottaridis
    Department of Haematology, University College London, London, United Kingdom
    Blood 98:1752-9. 2001
  9. ncbi VEGFR-1 (FLT-1), beta1 integrin, and hERG K+ channel for a macromolecular signaling complex in acute myeloid leukemia: role in cell migration and clinical outcome
    Serena Pillozzi
    Department of Experimental Pathology and Oncology, University of Firenze, Firenze, Italy
    Blood 110:1238-50. 2007
  10. ncbi The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia
    Lidia Larizza
    Department of Biology and Genetics for Medical Sciences, Medical Faculty, University of Milan, Italy
    Leuk Lymphoma 46:247-55. 2005

Detail Information

Publications354 found, 100 shown here

  1. ncbi Molecular classification of cancer: class discovery and class prediction by gene expression monitoring
    T R Golub
    Whitehead Institute Massachusetts Institute of Technology Center for Genome Research, Cambridge, MA 02139, USA
    Science 286:531-7. 1999
    ..A class discovery procedure automatically discovered the distinction between acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) without previous knowledge of these classes...
  2. pmc MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1
    Ramiro Garzon
    Department of Medicine, Ohio State University, Columbus, 43210, USA
    Blood 113:6411-8. 2009
    ..In the current study, we showed that enforced expression of miR-29b in acute myeloid leukemia cells resulted in marked reduction of the expression of DNA methyltransferases DNMT1, DNMT3A, and DNMT3B at ..
  3. ncbi Internal tandem duplication of the flt3 gene found in acute myeloid leukemia
    M Nakao
    Department of Internal Medicine III, Kyoto Prefectural University of Medicine, Japan
    Leukemia 10:1911-8. 1996
    We analyzed mRNA expression of the flt3 gene in 30 patients with acute myeloid leukemia (AML) and 50 with acute lymphoblastic leukemia (ALL)...
  4. ncbi Prognostically useful gene-expression profiles in acute myeloid leukemia
    Peter J M Valk
    Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
    N Engl J Med 350:1617-28. 2004
    In patients with acute myeloid leukemia (AML) a combination of methods must be used to classify the disease, make therapeutic decisions, and determine the prognosis...
  5. ncbi Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)
    John C Byrd
    Division of Hematology and Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus 43210 1240, USA
    Blood 100:4325-36. 2002
    We analyzed prospectively 1213 adults with de novo acute myeloid leukemia (AML) to ascertain the prognostic impact of cytogenetic abnormalities on complete remission (CR) rate, 5-year cumulative incidence of relapse (CIR), and 5-year ..
  6. ncbi The transcriptional network that controls growth arrest and differentiation in a human myeloid leukemia cell line
    Harukazu Suzuki
    RIKEN Omics Science Center, RIKEN Yokohama Institute, Kanagawa, Japan
    Nat Genet 41:553-62. 2009
    ....
  7. ncbi FLT3 mutations in acute myeloid leukemia cell lines
    H Quentmeier
    DSMZ German Collection of Microorganisms and Cell Cultures, Department of Human and Animal Cell Cultures, Braunschweig, Germany
    Leukemia 17:120-4. 2003
    ..point mutations of the receptor tyrosine kinase (RTK) FLT3 are found in a high proportion of cases with acute myeloid leukemia (AML)...
  8. ncbi The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United King
    P D Kottaridis
    Department of Haematology, University College London, London, United Kingdom
    Blood 98:1752-9. 2001
    In acute myeloid leukemia (AML), further prognostic determinants are required in addition to cytogenetics to predict patients at increased risk of relapse...
  9. ncbi VEGFR-1 (FLT-1), beta1 integrin, and hERG K+ channel for a macromolecular signaling complex in acute myeloid leukemia: role in cell migration and clinical outcome
    Serena Pillozzi
    Department of Experimental Pathology and Oncology, University of Firenze, Firenze, Italy
    Blood 110:1238-50. 2007
    ..FLT-1; (2) the human eag-related gene 1 (hERG1) K(+) channels; and (3) integrin receptors in acute myeloid leukemia (AML) cells. FLT-1, hERG1, and the beta(1) integrin were found to form a macromolecular signaling complex...
  10. ncbi The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia
    Lidia Larizza
    Department of Biology and Genetics for Medical Sciences, Medical Faculty, University of Milan, Italy
    Leuk Lymphoma 46:247-55. 2005
    The Kasumi-1 cell line is an intensively investigated model system of Acute Myeloid Leukemia with t(8;21) translocation, that represents 1 of the 2 main subtypes of Core Binding Factor Leukemia (CBFL)...
  11. ncbi Drug therapy for acute myeloid leukemia
    Martin S Tallman
    Northwestern University Feinberg School of Medicine, Division of Hematology Oncology, Robert H Lurie Comprehensive Cancer Center, 676 N St Clair St, Ste 850, Chicago, IL 60611, USA
    Blood 106:1154-63. 2005
    Although improvement in outcomes has occurred in younger adults with acute myeloid leukemia (AML) during the past 4 decades, progress in older adults has been much less conspicuous, if at all...
  12. ncbi Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm
    Stefan Fröhling
    Department of Internal Medicine III, University Hospital of Ulm, Germany
    Blood 100:4372-80. 2002
    ..of activating mutations of the FLT3 gene in homogeneously treated adults 16 to 60 years of age with acute myeloid leukemia (AML) and normal cytogenetics, pretreatment samples from 224 patients entered into 2 consecutive multicenter ..
  13. ncbi Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study
    Hagop Kantarjian
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:1794-803. 2006
    ..Decitabine indirectly depletes methylcytosine and causes hypomethylation of target gene promoters...
  14. ncbi Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic cell death of human myeloid leukemia HL-60 cells by a dietary compound withaferin A with concomitant protection by N-acetyl cysteine
    Fayaz Malik
    Division of Pharmacology, Indian Institute of Integrative Medicine, Council of Scientific and Industrial Research, Canal Road, Jammu Tawi 180001, India
    Apoptosis 12:2115-33. 2007
    ..The results of our studies demonstrate that withaferinA induced early ROS generation and mitochondrial dysfunction in cancer cells trigger events responsible for mitochondrial -dependent and -independent apoptosis pathways...
  15. pmc Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value
    Loredana Ruggeri
    Division of Hematology and Clinical Immunology, Department of Clinical and Experimental Medicine, University of Perugia, Istituto di Ricovero e Cura a Carattere Scientifico, Foundation on Transplantation Biotechnologies, Perugia, Italy
    Blood 110:433-40. 2007
    We analyzed 112 patients with high-risk acute myeloid leukemia (61 in complete remission [CR]; 51 in relapse), who received human leukocyte-antigen (HLA)-haploidentical transplants from natural killer (NK) alloreactive (n = 51) or non-NK ..
  16. ncbi Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia
    Kathryn Sibley
    Leukaemia Research Fund, Epidemiology and Genetics Unit, School of Medicine, University of Leeds, Leeds LS2 9JT, United Kingdom
    Cancer Res 63:4327-30. 2003
    ..In a case-control study of adult acute myeloid leukemia (AML), we show a significantly increased risk of AML associated with heterozygotes (GA) and homozygote ..
  17. ncbi Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential
    A M S Cheung
    Department of Medicine, The University of Hong Kong, Hong Kong, China
    Leukemia 21:1423-30. 2007
    ..is used to define normal hematopoietic stem cell (HSC), but its link to leukemic stem cells (LSC) in acute myeloid leukemia (AML) is currently unknown...
  18. ncbi Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia
    Shannon E Mullican
    Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, USA
    Nat Med 13:730-5. 2007
    ..The abrogation of these proteins in mice led to rapidly lethal acute myeloid leukemia (AML), involving abnormal expansion of hematopoietic stem cells (HSCs) and myeloid progenitors, decreased ..
  19. pmc Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia
    Shujun Liu
    Division of Hematology Oncology, The Ohio State University, Columbus, OH 43210, USA
    Cancer Cell 17:333-47. 2010
    ..of KIT overexpression that associates with KIT gain-of-function mutations occurring in subsets of acute myeloid leukemia (AML) (i.e., core binding factor AML) is unknown...
  20. ncbi PU.1 is a suppressor of myeloid leukemia, inactivated in mice by gene deletion and mutation of its DNA binding domain
    Wendy D Cook
    Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
    Blood 104:3437-44. 2004
    ..The results suggest that PU.1 normally suppresses development of myeloid leukemia by promoting differentiation and that the combination of gene deletion and a point mutation that impairs its ..
  21. pmc Myeloid leukemia factor 1 regulates p53 by suppressing COP1 via COP9 signalosome subunit 3
    Noriko Yoneda-Kato
    Department of Animal Molecular Genetics, Graduate School of Biological Sciences, Nara Institute of Science and Technology, Takayama, Ikoma, Nara, Japan
    EMBO J 24:1739-49. 2005
    b>Myeloid leukemia factor 1 (MLF1) was first identified as the leukemic fusion protein NPM-MLF1 generated by the t(3;5)(q25.1;q34) chromosomal translocation...
  22. ncbi Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia
    A M Martelli
    Cell Signalling Laboratory, Dipartimento di Scienze Anatomiche Umane e Fisiopatologia dell Apparato Locomotore, Sezione di Anatomia Umana, Universita di Bologna, Bologna, Italy
    Leukemia 20:911-28. 2006
    ..Recent studies showed that PI3K/Akt signaling is frequently activated in acute myeloid leukemia (AML) patient blasts and strongly contributes to proliferation, survival and drug resistance of these cells...
  23. ncbi Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission
    A van Rhenen
    Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
    Leukemia 21:1700-7. 2007
    Acute myeloid leukemia (AML) is generally regarded as a stem cell disease. In CD34-positive AML, the leukemic stem cell has been recognized as CD38 negative...
  24. ncbi Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis
    M Yanada
    Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan
    Leukemia 19:1345-9. 2005
    ..kinase domain (TKD) mutations, have been recognized in a substantial proportion of patients with acute myeloid leukemia (AML)...
  25. pmc Inactivation of PU.1 in adult mice leads to the development of myeloid leukemia
    Donald Metcalf
    The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville 3050, Victoria, Australia
    Proc Natl Acad Sci U S A 103:1486-91. 2006
    ..After a 13-week delay, conditionally deleted (PU.1(-/-)) mice began dying of myeloid leukemia, and 95% of the mice surviving from early postinduction death developed transplantable myeloid leukemia whose ..
  26. ncbi Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses
    Henry Y Li
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 101:3628-34. 2003
    ..Statins are also toxic to several malignancies, including acute myeloid leukemia (AML)...
  27. ncbi Control of differentiation and apoptosis of human myeloid leukemia cells by cytokinins and cytokinin nucleosides, plant redifferentiation-inducing hormones
    Yuki Ishii
    Saitama Cancer Center Research Institute, Saitama 362 0806, Japan
    Cell Growth Differ 13:19-26. 2002
    We examined the effects of various adenine analogues on the growth and differentiation of human myeloid leukemia HL-60 cells. Some of these analogues inhibit growth and induce nitroblue tetrazolium reducing activity in HL-60 cells...
  28. ncbi Increased nuclear expression and transactivation of vitamin D receptor by the cardiotonic steroid bufalin in human myeloid leukemia cells
    Yusuke Amano
    Division of Biochemistry, Department of Biomedical Sciences, Nihon University School of Medicine, Itabashi ku, Tokyo, Japan
    J Steroid Biochem Mol Biol 114:144-51. 2009
    ..D(3) [1,25(OH)(2)D(3)], is a potent ligand for the nuclear receptor vitamin D receptor (VDR) and induces myeloid leukemia cell differentiation...
  29. ncbi Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia
    B Douglas Smith
    Departments of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Blood 103:3669-76. 2004
    ..of FMS-like tyrosine kinase 3 (FLT3) are present in approximately 30% of patients with de novo acute myeloid leukemia (AML) and are associated with lower cure rates from standard chemotherapy-based treatment...
  30. ncbi Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia
    Pierre Sujobert
    Service d Hematologie, Hopital Cochin, AP HP, 27 rue du Faubourg Saint Jacques, 75014, Paris, France
    Blood 106:1063-6. 2005
    ..signaling pathway has been shown to be frequently activated in blast cells from patients with acute myeloid leukemia (AML) and to contribute to survival and proliferation of these cells...
  31. pmc A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines
    Paul W Hollenbach
    Celgene Corporation, San Francisco, California, United States of America
    PLoS ONE 5:e9001. 2010
    ..AZA) and decitabine (DAC) are used for the treatment of patients with myelodysplastic syndromes and acute myeloid leukemia (AML)...
  32. pmc Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?
    Krzysztof Mrozek
    Department of Internal Medicine, The Arthur G James Cancer Hospital and Richard J Solove Research Institute, Room 1248B, The Ohio State University, 300 West Tenth Ave, Columbus, OH 43210 1228, USA
    Blood 109:431-48. 2007
    Recent molecular analyses of leukemic blasts from pretreatment marrow or blood of patients with acute myeloid leukemia (AML) and a normal karyotype, the largest cytogenetic subset (ie, 40%-49%) of AML, have revealed a striking ..
  33. ncbi Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series
    Sonali M Smith
    Section of Hematology Oncology, Department of Medicine, MC2115, University of Chicago, 5841 S Maryland Avenue, Chicago, IL 60637, USA
    Blood 102:43-52. 2003
    Therapy-related myelodysplasia and myeloid leukemia (t-MDS/t-AML) is a distinctive clinical syndrome occurring after exposure to chemotherapy (CT) or radiotherapy (RT)...
  34. ncbi Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia
    Jochen Greiner
    Third Department of Internal Medicine, University of Ulm, Robert Koch Str 8, 89081 Ulm, Germany
    Blood 106:938-45. 2005
    ..To define T-cell epitopes of RHAMM/CD168 toward specific immunotherapies for acute myeloid leukemia (AML), 10 potential HLA-A2-binding RHAMM/CD168 peptides (R1 to R10) were synthesized based on computer ..
  35. ncbi Oligonucleotide array-CGH reveals cryptic gene copy number alterations in karyotypically normal acute myeloid leukemia
    A Tyybakinoja
    Leukemia 21:571-4. 2007
  36. ncbi CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia
    Carmen Scheibenbogen
    Medizinische Klinik III, Hämatologie, Onkologie und Transfusionsmedizin, Universitatsklinikum Benjamin Franklin, Freie Universitat Berlin, Hindenburgdamm 30, 12200 Berlin, Germany
    Blood 100:2132-7. 2002
    Wilms tumor gene product WT1 and proteinase 3 are overexpressed antigens in acute myeloid leukemia (AML), against which cytotoxic T lymphocytes can be elicited in vitro and in murine models...
  37. pmc axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase
    J P O'Bryan
    Curriculum in Genetics, Lineberger Cancer Research Center, University of North Carolina, Chapel Hill 27599
    Mol Cell Biol 11:5016-31. 1991
    ....
  38. ncbi Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells
    Zeev Estrov
    Department of Bioimmunotherapy, Box 422, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 102:987-95. 2003
    ..We investigated whether resveratrol is active against fresh acute myeloid leukemia (AML) cells and its mechanism of action...
  39. ncbi A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia
    G G Wulf
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
    Blood 98:1166-73. 2001
    The hematopoietic stem cell underlying acute myeloid leukemia (AML) is controversial...
  40. ncbi Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy
    Dawn Hershman
    Department of Medicine and Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    J Natl Cancer Inst 99:196-205. 2007
    ..Although these growth factors support chemotherapy, their long-term safety has not been evaluated. We studied the association between G-CSF use and incidence of leukemia in a population-based sample of breast cancer patients...
  41. ncbi Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study
    Peter Paschka
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 24:3904-11. 2006
    To analyze the prognostic impact of mutated KIT (mutKIT) in core-binding factor acute myeloid leukemia (AML) with inv(16)(p13q22) and t(8;21)(q22;q22).
  42. ncbi Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway
    K T Doepfner
    Division of Clinical Chemistry and Biochemistry, University Children s Hospital Zurich, Zurich, Switzerland
    Leukemia 21:1921-30. 2007
    ..Therefore, the role of insulin-like growth factor I (IGF-I) signaling in growth and survival of acute myeloid leukemia (AML) cells was investigated...
  43. ncbi An RNA-binding protein gene, TLS/FUS, is fused to ERG in human myeloid leukemia with t(16;21) chromosomal translocation
    H Ichikawa
    Radiobiology Division, National Cancer Center Research Institute, Tokyo, Japan
    Cancer Res 54:2865-8. 1994
    The t(16;21)(p11;q22) translocation is a recurrent chromosomal abnormality found in several types of myeloid leukemia. We have previously demonstrated that the breakpoints of this translocation are clustered in a specific intron of the ..
  44. ncbi Incidence of acute myeloid leukemia and hepatocellular carcinoma in mice irradiated with 1 GeV/nucleon (56)Fe ions
    Michael M Weil
    Department of Environmental and Radiological Health Sciences and, Colorado State University, Fort Collins, Colorado 80523, USA
    Radiat Res 172:213-9. 2009
    ..HZE species, 1 GeV (56)Fe ions, a component of space radiation, in a mouse model for radiation-induced acute myeloid leukemia. CBA/CaJ mice were irradiated with 1 GeV/nucleon (56)Fe ions or (137)Cs gamma rays and followed until they ..
  45. ncbi Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia
    Oliver Goodyear
    CRUK Institute for Cancer Studies, University of Birmingham, Birmingham
    Blood 116:1908-18. 2010
    ..and sodium valproate (VPA) up-regulate expression of melanoma-associated antigens (MAGE antigens) on acute myeloid leukemia (AML) and myeloma cell lines...
  46. ncbi Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction
    Cyril Fauriat
    Laboratoire d Immunologie des Tumeurs, Institut National de la Santé et de la Recherche Médicale INSERM Unite Mixté de Recherche UMR 599, Marseille, France
    Blood 109:323-30. 2007
    ..Analysis of in vitro IL-2-expanded NK cells from patients with myelocytic/monocytic acute myeloid leukemia (AML-NK cells) has revealed poor cytolytic functions because of deficient expression of pivotal activation ..
  47. ncbi A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia
    Ming Jer Huang
    Department of Medicine, Mackay Memorial Hospital, Taipei, Taiwan
    Exp Hematol 34:1480-9. 2006
    ..differentiation, and its aberrant expression is frequently seen in multiple human cancers, including acute myeloid leukemia (AML). As c-Myc heterodimerizes with Max to transactivate downstream target genes in leukemogenesis...
  48. ncbi High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients
    Sahar Barjesteh van Waalwijk van Doorn-Khosrovani
    Institute of Hematology, Erasmus Medical Centre, Rotterdam, Netherlands
    Blood 101:837-45. 2003
    ..The gene is aberrantly expressed in acute myeloid leukemia (AML) patients carrying 3q26 abnormalities...
  49. ncbi CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations
    Stefan Fröhling
    Department of Internal Medicine III, University Hospital of Ulm, Robert Koch Str 8, 89081 Ulm, Germany
    J Clin Oncol 22:624-33. 2004
    To assess the prognostic relevance of mutations in the CEBPA gene encoding CCAAT/enhancer binding protein alpha (C/EBP alpha) in a large prospective series of younger adults with acute myeloid leukemia (AML) and normal cytogenetics.
  50. ncbi Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality
    Naeem A Ali
    Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Ohio State University, Columbus, Ohio 43210, USA
    Cancer 110:96-102. 2007
    ..The authors hypothesized that hyperglycemia may be associated with adverse outcomes in patients with acute myeloid leukemia (AML) and sought to determine whether this association exists in this population.
  51. ncbi Aberrant methylation of multiple tumor suppressor genes in acute myeloid leukemia
    Cumhur G Ekmekci
    Genetics, Institute for Experimental Medicine, Istanbul University, Istanbul, Turkey
    Am J Hematol 77:233-40. 2004
    ..of tumors to incur nonrandom concurrent methylation, has been described in several tumors, including acute myeloid leukemia (AML)...
  52. ncbi Retinoids and myelomonocytic growth factors cooperatively activate RARA and induce human myeloid leukemia cell differentiation via MAP kinase pathways
    Annegret Glasow
    Section of Hematological Oncology, Institute of Cancer Research, London, United Kingdom
    Blood 105:341-9. 2005
    ..potentiate differentiation effects of ATRA in different AML cell lines and primary cells from patients with myeloid leukemia. The ligand-dependent activities of endogenous and transiently expressed retinoic acid receptor alpha (..
  53. pmc Calorie restriction reduces the incidence of myeloid leukemia induced by a single whole-body radiation in C3H/He mice
    K Yoshida
    Division of Biology and Oncology, National Institute of Radiological Sciences, Inage Ku, Chiba, Japan
    Proc Natl Acad Sci U S A 94:2615-9. 1997
    ..It is of interest to observe the effect of caloric restriction on radiation-induced myeloid leukemia, because the disease was observed to have been increased in the survivors of the atomic bombs in Hiroshima ..
  54. pmc CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age
    Marry M van den Heuvel-Eibrink
    Department of Hematology, P O Erasmus MC, Dr Molewaterplein 40, 3015 GJ, Rotterdam, The Netherlands
    Ann Hematol 86:329-37. 2007
    Clinical resistance to chemotherapy in acute myeloid leukemia (AML) is associated with the expression of the multidrug resistance (MDR) proteins P-glycoprotein, encoded by the MDR1/ABCB1 gene, multidrug resistant-related protein (MRP/..
  55. ncbi Gene deletion explains both in vivo and in vitro generated chromosome 2 aberrations associated with murine myeloid leukemia
    B J Alexander
    Molecular Cytogenetics Laboratory, University of Melbourne, Australia
    Leukemia 9:2009-15. 1995
    ..5 cM by microsatellite mapping of 22 radiation-induced F1 tumors. In addition, we have eliminated the possibility that imprinting ablates expression from the remaining undeleted chromosome...
  56. pmc The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA
    M von Lindern
    Department of Cell Biology and Genetics, Erasmus University, Rotterdam, The Netherlands
    Mol Cell Biol 12:1687-97. 1992
    The translocation (6;9) is associated with a specific subtype of acute myeloid leukemia (AML). Previously, it was found that breakpoints on chromosome 9 are clustered in one of the introns of a large gene named Cain (can)...
  57. ncbi Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance
    Myriam Alcalay
    IFOM IEO Campus, Via Adamello 16, 20139, Milan, Italy
    Blood 106:899-902. 2005
    ..The molecular signature of NPMc+ AML includes up-regulation of several genes putatively involved in the maintenance of a stem-cell phenotype, suggesting that NPMc+ AML may derive from a multipotent hematopoietic progenitor...
  58. ncbi High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival
    Anna van Rhenen
    Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
    Clin Cancer Res 11:6520-7. 2005
    In CD34-positive acute myeloid leukemia (AML), the leukemia-initiating event originates from the CD34(+)CD38(-) stem cell compartment...
  59. ncbi Causes of death--other than progressive leukemia--in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): the Dutch Childhood Oncology Group experience
    A M Slats
    Department of Pediatric Hematology Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Leukemia 19:537-44. 2005
    ..than resistant disease or relapse, in 875 children with acute lymphoblastic leukemia (ALL) and 229 with acute myeloid leukemia (AML), treated on three different Dutch Childhood Oncology Group (DCOG) ALL and three AML protocols...
  60. pmc The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript
    H Miyoshi
    Department of Immunology and Virology, Saitama Cancer Center Research Institute, Japan
    EMBO J 12:2715-21. 1993
    The t(8;21) translocation is one of the most frequent chromosome abnormalities in acute myeloid leukemia. It has been shown that the t(8;21) breakpoints on chromosome 21 cluster within a single specific intron of the AML1 gene, which is ..
  61. ncbi Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations
    Konstanze Dohner
    Department of Internal Medicine III, University Hospital of Ulm, Robert Koch Str 8, 89081 Ulm, Germany
    Blood 106:3740-6. 2005
    ..of mutations in the NPM1 gene encoding a nucleocytoplasmic shuttle protein in younger adults with acute myeloid leukemia (AML) and normal cytogenetics, sequencing of NPM1 exon 12 was performed in diagnostic samples from 300 ..
  62. ncbi Expression of breast cancer resistance protein in blast cells from patients with acute leukemia
    D D Ross
    University of Maryland Greenebaum Cancer Center the Department of Medicine, Division of Hematology Oncology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Blood 96:365-8. 2000
    ..We studied blast cells from 21 acute leukemia patients (20 acute myeloid leukemia, 1 acute lymphocytic leukemia) for the expression of BCRP mRNA using a quantitative reverse-transcription ..
  63. pmc Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461
    Sherif S Farag
    Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
    Blood 108:63-73. 2006
    We investigated the relative prognostic significance of cytogenetics in 635 adult acute myeloid leukemia (AML) patients 60 years of age or older treated on front-line protocols...
  64. ncbi Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance
    Roel G W Verhaak
    Department of Hematology, Erasmus University Medical Center Rotterdam, Ee1391a, Dr Molewaterplein 50, 3015 GE Rotterdam Z H, The Netherlands
    Blood 106:3747-54. 2005
    Mutations in nucleophosmin NPM1 are the most frequent acquired molecular abnormalities in acute myeloid leukemia (AML)...
  65. ncbi Downregulation of c-Myc is critical for valproic acid-induced growth arrest and myeloid differentiation of acute myeloid leukemia
    Yun Chih Cheng
    Department of Internal Medicine, Wanfang Hospital Taipei Medical University, Taipei, Taiwan
    Leuk Res 31:1403-11. 2007
    ..class of histone deacetylase inhibitor (HDACI), able to induce apoptosis and myeloid differentiation of acute myeloid leukemia (AML). In this study, we examined the underlying mechanisms in VPA-mediated activities in AML cells...
  66. ncbi Potential mechanisms of resistance to cytarabine in AML patients
    Carlos M Galmarini
    Unité INSERM 453, Laboratoire de Cytologie Analytique, Faculte de Medecine Rockefeller, 8, avenue Rockefeller, 69373 Lyon Cedex 08, France
    Leuk Res 26:621-9. 2002
    ..by reverse transcriptase polymerase chain reaction (rt-PCR), at diagnosis in the blast cells of 77 acute myeloid leukemia (AML) patients treated with ara-C, including 31 for whom samples were collected at first relapse...
  67. ncbi Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia
    Thomas Kindler
    Department of Hematology Oncology, Johannes Gutenberg University Mainz, Mainz, Germany
    Blood 103:3644-54. 2004
    ..was conducted to determine the efficacy and safety of imatinib mesylate in patients with c-kit-positive acute myeloid leukemia (AML) refractory to or not eligible for chemotherapy...
  68. pmc Expression profile of CREB knockdown in myeloid leukemia cells
    Matteo Pellegrini
    Department of Molecular, Cellular, and Developmental Biology, University of California, Los Angeles, USA
    BMC Cancer 8:264. 2008
    ..CREB knockdown inhibits leukemic cell proliferation in vitro and in vivo, but does not affect long-term hematopoietic reconstitution...
  69. pmc A mutation in the Icsbp1 gene causes susceptibility to infection and a chronic myeloid leukemia-like syndrome in BXH-2 mice
    Karine Turcotte
    Department of Biochemistry, McGill Cancer Center, McGill University, Montreal, Quebec H3G 1Y6, Canada
    J Exp Med 201:881-90. 2005
    BXH-2 mice develop a fatal myeloid leukemia by a two-step mutagenic process. First, a BXH-2-specific recessive mutation causes a myeloproliferative syndrome...
  70. ncbi Caffeic acid phenethyl ester induces mitochondria-mediated apoptosis in human myeloid leukemia U937 cells
    Un Ho Jin
    Department of Biological Sciences, Molecular and Cellular Glycobiology Unit, Sungkyunkwan University, 300 Chunchun dong, Jangan gu, Suwon City, Kyunggi Do 440 746, Korea
    Mol Cell Biochem 310:43-8. 2008
    ..In this study, we investigated the mechanism of CAPE-induced apoptosis in human myeloid leukemia U937 cells...
  71. ncbi MLL5, a homolog of Drosophila trithorax located within a segment of chromosome band 7q22 implicated in myeloid leukemia
    Brooke M Emerling
    Department of Pediatrics and Comprehensive Cancer Center, University of California, San Francisco, California, CA 94143, USA
    Oncogene 21:4849-54. 2002
    ..In a search for candidate myeloid leukemia tumor suppressor genes from a approximately 2...
  72. ncbi In vivo optical imaging of acute myeloid leukemia by green fluorescent protein: time-domain autofluorescence decoupling, fluorophore quantification, and localization
    Emmet McCormack
    Institute of Medicine, Haematology Section, Haukeland University Hospital, University of Bergen, Bergen, Norway
    Mol Imaging 6:193-204. 2007
    Human xenografts of acute myeloid leukemia (AML) in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice result in disease states of diffuse, nonpalpable tissue infiltrates exhibiting a variable disease course, with some ..
  73. ncbi Mutation analysis of PTEN/MMAC1 in acute myeloid leukemia
    T C Liu
    Division of Hematology Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
    Am J Hematol 63:170-5. 2000
    ..To evaluate the role of the PTEN/MMAC1 gene in leukemia, bone marrow and/or peripheral blood from 62 acute myeloid leukemia (AML) patients, 5 hemopoietic cell lines (HL60, U937, Raji, KG-1, K562), and 30 normal controls were analyzed...
  74. ncbi MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors
    Brian J P Huntly
    Division of Hematology, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Cancer Cell 6:587-96. 2004
    ..replated in methylcellulose cultures and continuously propagated in liquid culture, and resulted in an acute myeloid leukemia in vivo that could be serially transplanted...
  75. ncbi Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia
    T Padro
    Department of Medicine Hematology and Oncology, University of Muenster, Germany
    Leukemia 16:1302-10. 2002
    ..Thus, VEGF/VEGFR-2 might constitute promising targets for antiangiogenic and antileukemic treatment strategies in AML...
  76. ncbi Second hit mutations in the RTK/RAS signaling pathway in acute myeloid leukemia with inv(16)
    Peter J M Valk
    Haematologica 89:106. 2004
  77. ncbi A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment
    Alan K Burnett
    Department of Haematology, Wales School of Medicine, Cardiff University, Cardiff, United Kingdom
    Cancer 109:1114-24. 2007
    The survival of older patients with acute myeloid leukemia has not improved. Few clinical trials have been available for older patients who are not considered fit for an intensive chemotherapy approach.
  78. ncbi Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia
    Lisheng Wang
    Department of Pharmacology, The Ohio State University, Columbus, OH 43210, USA
    Blood 110:2075-83. 2007
    ..As such, CDK4/6 can be a therapeutic target in Flt3 ITD AML but also in primary Flt3 wt AML. Finally, acquired resistance to CDK4/6 inhibition can arise through activation CDK2...
  79. ncbi Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features
    Brunangelo Falini
    Institute of Hematology, University of Perugia, Italy
    Blood 109:874-85. 2007
    ..NPM1 mutations occur in 50% to 60% of adult acute myeloid leukemia with normal karyotype (AML-NK) and generate NPM mutants that localize aberrantly in the leukemic-cell ..
  80. ncbi Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations
    P Gorello
    Institute of Hematology, Department of Clinical and Experimental Medicine, University of Perugia, Perugia, Italy
    Leukemia 20:1103-8. 2006
    ..Thus, reliable, sensitive RQ-PCR assays for NPM1 mutations can now monitor and quantify MRD in AML patients with normal karyotype and NPM1 gene mutations...
  81. ncbi Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial
    Mats Brune
    Department of Hematology, University of Goteborg, Goteborg, Sweden
    Blood 108:88-96. 2006
    ..and histamine dihydrochloride (HDC) improved the leukemia-free survival (LFS) of adult patients with acute myeloid leukemia (AML) in complete remission (CR)...
  82. ncbi Heterozygous PU.1 mutations are associated with acute myeloid leukemia
    Beatrice U Mueller
    Harvard Institutes of Medicine, Harvard Medical School, Boston, MA, USA
    Blood 100:998-1007. 2002
    ..earliest stage of myeloid differentiation, similar to the blast cells that are the hallmark of human acute myeloid leukemia (AML). These facts led us to hypothesize that molecular abnormalities involving the PU...
  83. pmc Transcription profiling of C/EBP targets identifies Per2 as a gene implicated in myeloid leukemia
    Sigal Gery
    Cedars Sinai Medical Center, Davis Bldg 5066, 8700 Beverly Blvd, Los Angeles, CA 90048, USA
    Blood 106:2827-36. 2005
    ..Per2 levels were reduced in lymphoma cell lines and in acute myeloid leukemia (AML) patient samples. In addition, we generated stable K562 cells that expressed an inducible Per2 gene...
  84. ncbi Pediatric acute myeloid leukemia: towards high-quality cure of all patients
    Gertjan J L Kaspers
    Pediatric Oncology Hematology, VU University Medical Center, De Boelelaan 1117 NL 1081 HV Amsterdam, The Netherlands
    Haematologica 92:1519-32. 2007
    Prognosis of childhood acute myeloid leukemia (AML) has improved significantly over the past decades, from nearly no child surviving to a present probability of cure of approximately 60%...
  85. ncbi miR-34b targets cyclic AMP-responsive element binding protein in acute myeloid leukemia
    Martina Pigazzi
    Laboratory of Hematology Oncology, Department of Pediatrics, University of Padova, Padova, Italy
    Cancer Res 69:2471-8. 2009
    ..between miR-34b and CREB expression was found in a cohort of 78 pediatric patients at diagnosis of acute myeloid leukemia, supporting this relationship in vivo...
  86. ncbi Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia
    Jochen Greiner
    Third Department of Internal Medicine, University of Ulm, Ulm, Germany
    Exp Hematol 30:1029-35. 2002
    ..To identify new LAA, we used the method of serologic screening of cDNA expression libraries (SEREX)...
  87. ncbi Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia
    J Pedersen-Bjergaard
    The Chromosome Laboratory, Section of Hematology Oncology, Department of Clinical Genetics, Juliane Marie Center, Copenhagen, Denmark
    Leukemia 20:1943-9. 2006
    ..pathways were previously outlined in the pathogenesis of therapy-related myelodysplasia (t-MDS) and acute myeloid leukemia (t-AML) based on cytogenetic characteristics...
  88. ncbi Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia
    Elwin J C Rombouts
    Department of Hematology, Room Ee1391, PO Box 1738, 3000 DR Rotterdam, The Netherlands
    Blood 104:550-7. 2004
    ..analogous to normal hematopoietic cells, the level of CXC chemokine receptor 4 (CXCR-4) expression on acute myeloid leukemia (AML) cells correlates with stromal cell derived factor-1 alpha (SDF-1)-induced chemotaxis...
  89. ncbi Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia
    S Meshinchi
    The Fred Hutchinson Cancer Research Center, and University of Washington Medical Center, Seattle, WA 98103, USA
    Blood 97:89-94. 2001
    ..002). Multivariate analysis demonstrated that presence of the Flt3/ITD was the single most significant, independent prognostic factor for poor outcome (P =.009) in pediatric AML...
  90. ncbi A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy
    Steven Knapper
    Department of Haematology, Cardiff University School of Medicine, Heath Park, Cardiff, CF14 4XW, United Kingdom
    Blood 108:3262-70. 2006
    ..mutations of FMS-like tyrosine kinase 3 (FLT3) are present in approximately one third of patients with acute myeloid leukemia (AML) and are associated with adverse prognosis...
  91. ncbi Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia
    L Wang
    University Department of Haematology, Royal Liverpool University Hospital, Liverpool, UK
    Clin Pharmacol Ther 83:258-64. 2008
    Some chronic myeloid leukemia (CML) patients do not respond to imatinib, whereas others lose an initial response...
  92. ncbi Acute myeloid leukemia: epidemiology and etiology
    Barbara Deschler
    Department of Hematology Oncology, University of Freiburg, Freiburg, Germany
    Cancer 107:2099-107. 2006
    ..In contrast to these genetic alterations, epigenetic lesions, e.g., promoter silencing by hypermethylation of the p15/INK4b and other genes, are increasingly recognized as important in the pathogenesis of AML...
  93. ncbi In utero origin of t(8;21) AML1-ETO translocations in childhood acute myeloid leukemia
    Joseph L Wiemels
    Laboratory for Molecular Epidemiology, Department of Epidemiology and Biostatistics, University of California San Francisco 94143 0560, USA
    Blood 99:3801-5. 2002
    ..We now report evidence for the prenatal origin of a translocation in childhood acute myeloid leukemia (AML)...
  94. ncbi Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1
    E Bonhoure
    INSERM, U466, Toulouse F 31432, France
    Leukemia 20:95-102. 2006
    ..balance, in susceptibility to antineoplastic agents of either sensitive or multidrug-resistant acute myeloid leukemia cells...
  95. ncbi BMI-1 is highly expressed in M0-subtype acute myeloid leukemia
    Masashi Sawa
    Department of Molecular Medicine and Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan
    Int J Hematol 82:42-7. 2005
    ..Here, we quantitatively examined BMI-1 expression level in samples from patients with acute myeloid leukemia (AML) and other hematologic malignancies...
  96. ncbi Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia
    Regis T Costello
    Unité d Immunologie des Tumeurs Département d Hématologie, Institut Paoli Calmettes, Universite de la Mediterranee, Marseille, France
    Blood 99:3661-7. 2002
    ..Here, we analyzed the cytolytic function of NK cells obtained from patients with acute myeloid leukemia (AML)...
  97. ncbi MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia
    Scott A Armstrong
    Departments of Pediatric Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Nat Genet 30:41-7. 2002
    ..Establishing that MLL is a unique entity is critical, as it mandates the examination of selectively expressed genes for urgently needed molecular targets...
  98. pmc CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia
    Naoki Hosen
    Department of Pathology, Institute of Stem Cell Biology and Regenerative Medicine, Stanford Cancer Center, Stanford University School of Medicine, Stanford, CA 94305 5323, USA
    Proc Natl Acad Sci U S A 104:11008-13. 2007
    Permanent cure of acute myeloid leukemia (AML) by chemotherapy alone remains elusive for most patients because of the inability to effectively eradicate leukemic stem cells (LSCs), the self-renewing component of the leukemia...
  99. pmc CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy
    Roland B Walter
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 109:4168-70. 2007
    ..Studying patients undergoing GO monotherapy for relapsed acute myeloid leukemia (AML), we now find that AML blasts of responders have a significantly higher mean CD33 level and lower P-..
  100. pmc The ETO protein disrupted in t(8;21)-associated acute myeloid leukemia is a corepressor for the promyelocytic leukemia zinc finger protein
    A M Melnick
    Department of Medicine, Mount Sinai School of Medicine, New York, New York 10029, USA
    Mol Cell Biol 20:2075-86. 2000
    ..by its fusion to the AML-1 transcription factor in translocation (8;21) associated with the M2 form of acute myeloid leukemia (AML)...
  101. ncbi Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)
    Elihu Estey
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Blood 109:1395-400. 2007
    ..transplantation (RIC-HSCT), we wrote a protocol in which all untreated patients 50 years or older with acute myeloid leukemia (AML) and unfavorable cytogenetics would be evaluated during induction for a possible RIC-HSCT in first ..

Research Grants78

  1. Preclinical Development of JS-K, a Novel NO-Generating Prodrug for Cancer
    Paul J Shami; Fiscal Year: 2012
    ..In mouse xenograft models of human tumors, JS-K is highly effective against acute myeloid leukemia, prostate cancer, hepatocellular carcinoma, multiple myeloma and non-small cell lung cancer...
  2. ICSBP Function During Myeloid Differentiation
    ELIZABETH ANN EKLUND; Fiscal Year: 2011
    ..of evidence suggest that the interferon consensus sequence binding protein (ICSBP or IRF8) functions as a myeloid leukemia tumor-suppressor...
  3. Arsenic Trioxide and Acute Myeloid Leukemia
    Yongkui Jing; Fiscal Year: 2012
    ..Our goal will be to utilize As2O3 in combination with 4 HPR or EA analogs in clinical trials in patients with refractory, secondary or in elderly patients with acute myelogenous leukemia. ..
  4. Cell signaling as a leukemia biomarker
    JAMES WILLIAM JACOBBERGER; Fiscal Year: 2013
    ..One model for the genesis of acute myeloid leukemia (AML) is that at least two mutations are leukemogenic: 1) in a transcription factor that alters ..
  5. Molecular Mechanisms of Disease Progression in Myeloid Malignancy
    ELIZABETH ANN EKLUND; Fiscal Year: 2013
    ..Fas-resistance, and increased bcatenin activity are associated with poor prognosis in chronic myeloid leukemia (CML)...
  6. Cellular and Animal Models of FUS Mutations in ALS
    Eric J Huang; Fiscal Year: 2013
    ..on human chromosome 16 is originally identified to encode an oncogene implicated in malignant liposarcoma and myeloid leukemia. More recent evidence shows that mutations in FUS/TLS are found in familial cases of amyotrophic lateral ..
  7. SATB1-dependent epigenetic regulation of leukemia initiating cells
    Britta Will; Fiscal Year: 2011
    ..apos;epi-genetic') factor we have found in normal blood stem cells and cells that initiate acute myeloid leukemia (AML)...
  8. Validation of microRNAs as therapeutic targets in hematological malignancies
    Natarajan Muthusamy; Fiscal Year: 2013
    ..of miR-29b in the pathogenesis of epigenetic progression in chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) through modulation of DNA methyltransferases [DNMT1, DNMT3A and DNMT3B], DNA hypermethylation and gene ..
  9. Bone Marrow Transplantation for Hematologic Malignancies using Novel Radioimmunot
    John M Pagel; Fiscal Year: 2013
    Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) currently kill the majority of afflicted patients despite treatment with combination chemotherapy and hematopoietic cell transplantation (HCT)...
  10. Analysis of the leukemic stem cell niche in chronic myeloid leukemia
    DANIELA SANDRA KRAUSE; Fiscal Year: 2013
    ..I have chosen to focus my research on analyzing the LSC niche in chronic myeloid leukemia (CML), as understanding of the biology of the LSC niche and, ultimately, the development of strategies to ..
  11. Using Mass Spectroscopy to Characterize Transcription Proteins and F2-Isoprostane
    BETTYE HENNINTON; Fiscal Year: 2011
    ..evidence for a human homolog, MLL3, that is found on a region of chromosome 7 that is frequently deleted in myeloid leukemia (3)...
  12. Post-translational regulation of MLL in leukemogenesis
    ANDREW GEORGE MUNTEAN; Fiscal Year: 2012
    ..mechanisms for both wild type MLL and MLL fusion proteins which may be disrupted for therapeutic value in myeloid leukemia. Current research focuses on a novel physical interaction between MLL and the Polymerase Associated Factor ..
  13. Post-translational regulation of MLL in leukemogenesis
    ANDREW GEORGE MUNTEAN; Fiscal Year: 2013
    ..mechanisms for both wild type MLL and MLL fusion proteins which may be disrupted for therapeutic value in myeloid leukemia. Current research focuses on a novel physical interaction between MLL and the Polymerase Associated Factor ..
  14. Mechanisms of cancer initiation by TRIM32
    Molly F Kulesz-Martin; Fiscal Year: 2012
    ..downregulation is prognostic for conversion from myelodysplastic syndrome (MDS) to later stages and chronic myeloid leukemia (CML)...
  15. FASEB SRC on Hematopoietic Malignancies
    MICHELLE ALICE KELLIHER; Fiscal Year: 2011
    ..will highlight recent advances in biology and treatment of a wide spectrum of blood cancers, including acute myeloid leukemia, acute lymphoid leukemia, myeloma, myeloproliferative neoplasms and myeloproliferative diseases...
  16. Functional Genomics Approach to the Role of the JAK/STAT and MAPK Pathway in CBD
    Li Li; Fiscal Year: 2013
    ..Her research focused on the development of novel immunotherapeutic strategies for patients with acute myeloid leukemia (AML)...
  17. Role of FA proteins in hematopoiesis
    Qishen Pang; Fiscal Year: 2013
    ..hematopoietic stem and progenitor (HSC/P) cells, and progression to myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)...
  18. Genome instability in leukemia stem cell
    Tomasz Skorski; Fiscal Year: 2010
    ..kinase transforms hematopoeitic stem cells (HSCs) into leukemia stem cells (LSCs) and induces chronic myeloid leukemia in chronic phase (CML-CP)...
  19. Cytotoxic-T-Lymphocyte (CTL) Therapy of AML
    Bruce R Blazar; Fiscal Year: 2013
    ..provided by applicant): Allogeneic bone marrow transplantation (BMT) can cure patients with risk acute myeloid leukemia (AML). Post-BMT recipients are highly susceptible to T cell responsive viral and fungal infections...
  20. Identification of novel target genes for polycythemia vera (PV)
    Shaoguang Li; Fiscal Year: 2013
    ..Similar to chromosome- positive (Ph+) chronic myeloid leukemia (CML), these Philadelphia chromosome-negative (Ph-) MPNs are also derived from hematopoietic stem cells (HSCs)..
  21. Impact of genetic variation on response to GO therapy in COG-AML clinical trials
    ROLAND BRUNO WALTER; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): An emerging approach in acute myeloid leukemia (AML) uses monoclonal antibodies as a means to deliver targeted therapy...
  22. Aberrant activation of HGF/MET signaling as a therapeutic target in AML
    Alex Kentsis; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Despite improvement in treatment of acute myeloid leukemia (AML), high-risk disease such as complex karyotype AML remains largely refractory to current therapy, and is mostly fatal...
  23. The role of ICSBP in the pathogenesis of chronic myeloid leukemia
    ELIZABETH ANN EKLUND; Fiscal Year: 2013
    ..and increased ?catenin activity are associated with poor prognosis and disease progression in chronic myeloid leukemia (CML)...
  24. System for Rapid Generation of Aptamers for Transplant Therapies
    KAREN QIAN; Fiscal Year: 2010
    ..an important treatment option for many patients with hematologic malignancies and solid tumors such as acute myeloid leukemia, myelodysplastic syndromes, chronic myeloid leukemia, systemic mastocytosis and breast cancer...
  25. Regulators of Cancer-Specific DNA Hypermethylation.
    Jean Pierre J Issa; Fiscal Year: 2013
    ..aim 1, we propose (a) to measure the propensity of promoter-associated CpG islands to DNA hypermethylation in myeloid leukemia and colorectal carcinomas) and (b) to identify the genomic (transcription factor binding sites, ..
  26. Study DNA repair in preventing MDS and AML after radiation and benzene exposure
    EDWARD PAUL HASTY; Fiscal Year: 2013
    ..syndrome (MDS) is a group of disorders characterized by dysfunctional blood cells that can progress to acute myeloid leukemia (AML)...
  27. AID-mediated genetic instability in BCR-ABL1-transformed B cell lineage leukemia
    MARKUS MUSCHEN; Fiscal Year: 2013
    ..kinase is not only expressed in Ph+ ALL (mainly p190 BCR-ABL1) but also in >95% of cases of chronic myeloid leukemia (CML;mainly p210 BCR-ABL1)...
  28. The p110 alpha and delta isoforms of PI3 kinase in hematopoiesis and leukemia
    Kira Gritsman; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Acute myeloid leukemia (AML) affects 1 in 25,000 people per year, and is curable in only about 40% of cases...
  29. HoxA10 Function During Myeloid Differentiation
    ELIZABETH ANN EKLUND; Fiscal Year: 2011
    ..First, overexpression of HoxA7-11 is common in human acute myeloid leukemia (AML) and murine leukemogenesis models...
  30. Validation and Development of WEE1 as a therapeutic target in AML
    Christopher C Porter; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Survival rates for patients with acute myeloid leukemia (AML) remain low, despite the fact that knowledge of the molecular events that cause AML has evolved rapidly in the last decade...
  31. Targeting aberrant epigenetics by nanomedicine
    Shujun Liu; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Acute myeloid leukemia (AML) represents one of the most common adult leukemia and remains as a deadly disease for most patients...
  32. IL-15 Characterization Through Experimental Immunology
    Michael A Caligiuri; Fiscal Year: 2013
    ..It will also likely be useful for modulating the immune system in treating acute myeloid leukemia, for providing new insights into mucosal immunity that will likely be important for oral vaccine development, ..
  33. Modulation of T cell Homeostasis in Myelodysplastic Syndrome (MDS)
    Javier Pinilla; Fiscal Year: 2012
    ..hematopoiesis that leads to single or multi-lineage peripheral cytopenias with the development of acute myeloid leukemia (AML) in approximately 30-40% of cases...
  34. High Throughput Transcriptome Sequencing for Systematic Detection of Recurrent Tr
    Chandan Kumar; Fiscal Year: 2012
    ..successful diagnostic/ prognostic markers and therapeutic targets such as the BCR-ABL1 gene fusion in Chronic Myeloid Leukemia, PDGFR mutation in gastrointestinal stromal tumors, ERBB2 amplification in breast cancers, and EGFR mutations ..
  35. Development of Inhibitors of the Leukemia Fusion Protein CBFbeta-SMMHC
    Roger A Rajewski; Fiscal Year: 2013
    ..CBF2 (CBFB) is disrupted by the chromosome 16 inversion [inv(16)(p13q22)], associated with ~12% of acute myeloid leukemia in humans, resulting in a fusion protein containing most of the CBF2 fused to the coiled-coil tail region of ..
  36. ROR1 as a Therapeutic Target in Acute Lymphoblastic Leukemia
    JEFFREY WALLACE TYNER; Fiscal Year: 2011
    ..clinical outcomes for patients with a variety of cancer diagnoses, most notably patients with chronic myeloid leukemia. To expand this targeted-therapy approach to all forms of cancer, disease-causing genes must first be ..
  37. Gene Targeted Therapy of Brain Tumors
    John H Sampson; Fiscal Year: 2010
    ..examples of trastuzumab for HER2-expressing breast cancer and imatinib for Philadelphia chromosome chronic myeloid leukemia. Similarly, support for the basic concept that genetic analysis can inform targeted therapy in GBM has ..
  38. Combinatorial Profiling and Characterization of AML1 Function in Hematopoiesis
    Kentson Lam; Fiscal Year: 2013
    ..AML1 was originally cloned from human acute myeloid leukemia cells with a translocation involving chromosomes 8 and 21...
  39. Myxoma Virus (MV) Oncolysis for treating human cancer
    Grant McFadden; Fiscal Year: 2013
    ..2) Optimize MV ex vivo cancer cell purging: Two human cancers, B-cell lymphoma and acute myeloid leukemia, will be investigated for the ability of ex vivo MV purging to eliminate their tumorigenic potential in vivo ..
  40. Role of Vav and Rac in KIT oncogenesis
    Reuben Kapur; Fiscal Year: 2013
    ..have been described in germ cell tumors, gastrointestinal stromal tumors (GISTs), sinonasal lymphomas, acute myeloid leukemia (AML), and systemic mastocytosis (SM)...
  41. Role of p27 in chronic myeloid leukemia and its potential as a therapeutic target
    Anupriya Agarwal; Fiscal Year: 2012
    ..Research: The objective of the proposed study is to determine the mechanism of p27 deregulation in chronic myeloid leukemia (CML) and to establish the role of p27 in CML pathogenesis...
  42. Experimental Therapeutics in Acute Leukemias
    William G Blum; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): The majority of adults with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) eventually relapse, and those with relapsed disease have a high likelihood of treatment failure with ..
  43. The Role of the APC Tumor Suppressor Gene in Hematopoiesis and Leukemogenesis
    Zhijian Qian; Fiscal Year: 2013
    ..high frequency in patients with primary MDS (10-15%) or therapy-related MDS (t-MDS) and therapy-related acute myeloid leukemia (t-AML) (40%)...
  44. ROR1 as a Therapeutic Target in Acute Lymphoblastic Leukemia
    JEFFREY WALLACE TYNER; Fiscal Year: 2013
    ..clinical outcomes for patients with a variety of cancer diagnoses, most notably patients with chronic myeloid leukemia. To expand this targeted-therapy approach to all forms of cancer, disease-causing genes must first be ..
  45. Mechanisms of adhesion and growth control in stem cells
    Reuben Kapur; Fiscal Year: 2010
    ..in stem/progenitor cells have been shown to result in myeloproliferative disease (MPD) as well as acute myeloid leukemia (AML)...
  46. PROCESSED ANTIGEN CHARACTERIZATION BY MASS SPECTROMETRY
    Donald F Hunt; Fiscal Year: 2012
    ..should make it possible to extend adoptive T-cell therapy to a number of other cancers including acute myeloid leukemia, chronic lymphocytic leukemia, pancreatic-,colorectal- and heptocellullar- adenocarcinoma and renal cancer...
  47. Role of JAK2V617F in the Pathogenesis of Myeloproliferative Disorders.
    Golam Mohi; Fiscal Year: 2013
    ..For example, BCR-ABL, the product of Philadelphia chromosome translocation, is associated with chronic myeloid leukemia (CML)...
  48. Regulation of Hematopoietic Progenitors by de novo DNA Methylation
    Margaret Goodell; Fiscal Year: 2013
    ..MDS incidence increases with age, has substantial pathologic impact, and is sometimes a precursor to acute myeloid leukemia (AML)...
  49. Elucidating the role of TIN2L at the telomere and in dyskeratosis congenita
    Nya D Nelson; Fiscal Year: 2013
    ..Patients with DC have a particularly high risk of developing acute myeloid leukemia and tongue cancer in comparison to the general population, 200 and 1100 fold respectively...
  50. Validating Syk as a Target for AML Therapy
    Kimberly Stegmaier; Fiscal Year: 2013
    PROJECT ABSTRACT Little progress has been made in the treatment of acute myeloid leukemia (AML) despite dose intensification of cytotoxic chemotherapy...
  51. Function of MTG16/ETO2 in acute leukemia
    SCOTT HIEBERT; Fiscal Year: 2010
    ..on chromosome 16 (MTG16, also known as Eto2) is disrupted by the t(16;21) chromosomal translocation in acute myeloid leukemia (AML), and this translocation is most commonly associated with therapy-related AML...
  52. NEXT GENERATION SEQUENCING ADD-ON-PHARMACOGENOMICS RESEARCH NETWROK (PGRN)
    Elaine R Mardis; Fiscal Year: 2013
    ..has resulted in an expansion of our understanding of mutations occurring in lung adenocarcinoma, acute myeloid leukemia, and glioblastoma multiforme...
  53. Inhibition of Histone Deacetylase in Myeloproliferative Neoplasms
    Golam Mohi; Fiscal Year: 2012
    ..There is evidence that JAK2V617F- negative acute myeloid leukemia occurs frequently in patients with a JAK2V617F-positive MPN, raising the possibility that JAK2 inhibitor ..
  54. Targeted Improvement in Stem Cell Therapy for Leukemia and Bone Marrow Failure Sy
    Qishen Pang; Fiscal Year: 2013
    ..FA) is a major inherited bone marrow (BM) failure syndrome with extremely high risk of developing acute myeloid leukemia (AML)...
  55. Efficacy and safety of novel CD80 IL15 IL15Ra expressing autologous AML vaccines
    KARIN L GAENSLER; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Our goal is to improve survival in older acute myeloid leukemia (AML) patients using optimized, genetically engineered, autologous AML cell vaccines...
  56. Pharmacogenetics of Ara-C Metabolic Pathway
    Jatinder K Lamba; Fiscal Year: 2012
    The nucleoside analog cytarabine (ara-C) has been the mainstay of acute myeloid leukemia (AML) chemotherapy for more than 40 years and is one of the most important drugs used to induce remission in patients with AML...
  57. ADVANCED TECHNOLOGY FOR ASSAYING CANCER-DRUG RESISTANCE
    Mark Lim; Fiscal Year: 2010
    ..This problem is exemplified by drug resistance developed in patients treated for chronic myeloid leukemia (CML) with the small molecule drug Imatinib (Gleevec/Glivec/STI571)...
  58. Role of U19/Eaf2 in androgen-dependent prostate homeostasis
    Zhou Wang; Fiscal Year: 2013
    ..and termed ELL-associated factor (Eaf2), based on its association with ELL, a fusion partner of MLL in acute myeloid leukemia. Preliminary studies showed that the ELL-binding region of U19 is critical for apoptosis induction...
  59. Regulation and Function of C/EBP in UVB Responses
    Robert C Smart; Fiscal Year: 2010
    ..C/EBPa has been implicated as a human tumor suppressor in acute myeloid leukemia and our results in experimental systems suggest C/EBPa negatively regulates keratinocyte growth and may have ..
  60. Sensitizing Leukemia Stem Cells to NF-kB Inhibition by Blocking TNF Signaling
    Andrew Volk; Fiscal Year: 2013
    ..a transcriptional regulator of many survival genes) resulted in significant death of LSCs in human acute myeloid leukemia samples while preserving healthy hematopoietic stem cells /progenitors (HSC/Ps)...
  61. Targeting the ROS-p38 MAPK Pathway as a Novel Strategy for Stem Cell Expansion
    GAVIN YONG WANG; Fiscal Year: 2012
    ..stem cells (HSCs) for transplantation therapy is rapidly expanding, particularly for the treatment of acute myeloid leukemia. However, CB-derived HSCs are of limited use in adults because the number of HSCs available in CB is not ..
  62. Acetylation-Dependent IFN Signal Transduction
    Y Eugene Chin; Fiscal Year: 2010
    ..in nearly all kinds of cell types, and are efficacious in the treatment of malignancies such as chronic myeloid leukemia. In recent years, the usage of IFN for solid cancer chemotherapy has received considerable attention...
  63. C-FES PROTEIN-TYROSINE KINASE IN MYELOID DIFFERENTIATION
    Robert Glazer; Fiscal Year: 1993
    ..how a myeloid-specific proto- oncogene protein-tyrosine kinase, c-fes can regulate the differentiation of myeloid leukemia cells...
  64. Targeting the leukemia microenvironment by CXCR4 inhibition in stem cell transpla
    Marina Y Konopleva; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): The prognosis of patients with relapsed acute myeloid leukemia (AML) is extremely poor...
  65. MULTIPLE CHIMERIC TRANSCRIPTS IN THE T(3--21)
    Giuseppina Nucifora; Fiscal Year: 1999
    ..in the malignant cells of patients with chronic myelogenous leukemia in blast crisis and with acute myeloid leukemia primarily following treatment with topoisomerase II inhibitors. The gene that is involved at 21q22 is AML1...
  66. MECHANISM OF GENE ACTIVATION BY DNA METHYLASE INHIBITORS
    Edward Newman; Fiscal Year: 2001
    5-Aza-2'-deoxycytidine (DAC) is an investigational agent with demonstrated activity in the treatment of acute myeloid leukemia and likely therapeutic utility in other leukemias and myelodysplastic syndromes...
  67. Molecular Studies of Severe Congenital Neutropenia
    Andrew Aprikyan; Fiscal Year: 2005
    ..SCN is usually diagnosed in early childhood and may evolve to acute myeloid leukemia. The severity of symptoms and risk of serious infections are in general inversely proportional to absolute ..
  68. Single Cell Diagnosis of Leukemia using Multiplex Nested PCR System
    WINSTON Z HO; Fiscal Year: 2010
    ..based on multiplexed PCR results;and analyze the presence or absence of chimeric BCR/ABL mRNAs for chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)...
  69. NOVEL DIFFERENTIATION AGENTS AGAINST HUMAN LEUKEMIAS
    Krzysztof Pankiewicz; Fiscal Year: 2000
    The overall aim of this proposal is to develop novel new agents for treatment of acute myeloid leukemia (AML) and chronic myeloid leukemia (CML)...
  70. NF1 GENE IN MYELOID LEUKEMIA AND CYTOKINE SIGNALING
    DAVID LARGAESPADA; Fiscal Year: 2002
    ..investigator's abstract) Treatment of childhood myelodysplastic syndromes (MDS) as well as chronic and acute myeloid leukemia (CML and AML) remains disappointing compared with well known advances in the treatment of childhood ..
  71. PROTEINASE 3 SPECIFIC IMMUNOTHERAPY OF LEUKEMIA
    Jeffrey Molldrem; Fiscal Year: 2002
    ..Pr3 is overexpressed by 3 to 6 fold in 75 percent of chronic myeloid leukemia (CML) and 50 percent of acute myeloid leukemia (AML) cells...
  72. CLONALITY IN ACUTE MYELOID LEUKEMIA AND MYELODYSPLASIA
    Donald Kufe; Fiscal Year: 1992
    ..proposal is to apply molecular biological analysis of clonal growth and growth factor expression in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)...
  73. Leukemia Signatures for Risk Classification & Targeting
    Cheryl Willman; Fiscal Year: 2009
    ..and relapsed ALL in adults;3) acute leukemia arising in infants less than 1 year of age;and 4) acute myeloid leukemia (AML) in children and adults...
  74. Predictors of Adult Leukemia
    Julie Ross; Fiscal Year: 2009
    ..a concurrent study of chronic lymphocytic leukemia (CLL) in southern Minnesota, we will focus this study on myeloid leukemia including acute myeloid leukemia (AML) and chronic myelogenous leukemia (CML)...
  75. MOLECULAR MECHANISMS IN EVI1-INDUCED MYELOID LEUKEMIA
    Archibald Perkins; Fiscal Year: 2000
    DESCRIPTION: (adapted from the investigator's abstract) Acute myeloid leukemia is a lethal illness whose molecular etiology is poorly understood, but which likely involves alterations in the ability of myeloid cells to control growth and ..
  76. Histone Deacetylase Inhibitors in CML
    Kapil Bhalla; Fiscal Year: 2009
    ..tyrosine kinase (TK) is a client protein of heat shock protein (hsp) 90 and the molecular hallmark of chronic myeloid leukemia (CML). Accordingly, lowering the levels of Bcr-Abl, e.g...
  77. Maintenance therapy with decitabine for acute myeloid leukemia in first remission
    William G Blum; Fiscal Year: 2010
    ..Many genes are frequently methylated in acute myeloid leukemia (AML) including p15, estrogen receptor (ER), and calcitonin, among others...
  78. Cyclin A1 as a Target in AML and Other Cancers
    DEBRA WOLGEMUTH; Fiscal Year: 2003
    ..Human cyclin A1 is also highly expressed in leukemic cells from patients with acute myeloid leukemia. To test the hypothesis that the aberrant high levels of cyclin A1 were causal in the leukemic phenotype, i.e...